CN113710264A - 用于治疗眼部疾病的组合物和方法 - Google Patents

用于治疗眼部疾病的组合物和方法 Download PDF

Info

Publication number
CN113710264A
CN113710264A CN202080030026.4A CN202080030026A CN113710264A CN 113710264 A CN113710264 A CN 113710264A CN 202080030026 A CN202080030026 A CN 202080030026A CN 113710264 A CN113710264 A CN 113710264A
Authority
CN
China
Prior art keywords
seq
peptide
unit dose
salt
abu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080030026.4A
Other languages
English (en)
Chinese (zh)
Inventor
尼兰詹·B·潘迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asclepix Therapeutics Inc
Original Assignee
Asclepix Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asclepix Therapeutics Inc filed Critical Asclepix Therapeutics Inc
Publication of CN113710264A publication Critical patent/CN113710264A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN202080030026.4A 2019-03-26 2020-03-26 用于治疗眼部疾病的组合物和方法 Pending CN113710264A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962824017P 2019-03-26 2019-03-26
US62/824,017 2019-03-26
PCT/US2020/024972 WO2020198481A1 (en) 2019-03-26 2020-03-26 Compositions and methods for treating ocular disease

Publications (1)

Publication Number Publication Date
CN113710264A true CN113710264A (zh) 2021-11-26

Family

ID=72609544

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080030026.4A Pending CN113710264A (zh) 2019-03-26 2020-03-26 用于治疗眼部疾病的组合物和方法

Country Status (12)

Country Link
US (1) US12540171B2 (cg-RX-API-DMAC7.html)
EP (1) EP3946418A4 (cg-RX-API-DMAC7.html)
JP (1) JP7650074B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210146352A (cg-RX-API-DMAC7.html)
CN (1) CN113710264A (cg-RX-API-DMAC7.html)
AU (1) AU2020248438A1 (cg-RX-API-DMAC7.html)
CA (1) CA3134816A1 (cg-RX-API-DMAC7.html)
EA (1) EA202192607A1 (cg-RX-API-DMAC7.html)
IL (1) IL286625A (cg-RX-API-DMAC7.html)
MX (1) MX2021011727A (cg-RX-API-DMAC7.html)
WO (1) WO2020198481A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202107235B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023222134A1 (zh) * 2022-05-20 2023-11-23 杭州禾泰健宇生物科技有限公司 一种类肽化合物及其应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105431162A (zh) * 2013-06-07 2016-03-23 约翰霍普金斯大学 用于治疗血管生成依赖性和淋巴管生成依赖性疾病的生物模拟肽和生物可降解的递送平台
WO2018208829A1 (en) * 2017-05-08 2018-11-15 Asclepix Therapeutics, Llc Biodegradable microparticles for sustained delivery of anti-angiogenic peptide
US20180339024A1 (en) * 2015-11-19 2018-11-29 Asclepix Therapeutics, Llc Peptides with anti-angiogenic, anti-lymphangiogenic, and anti-edemic properties and nanoparticle formulations
WO2019028427A1 (en) * 2017-08-03 2019-02-07 Asclepix Therapeutics, Llc. METHODS OF IDENTIFYING AND PREPARING PHARMACEUTICAL AGENTS TO ACTIVATE TIE2 RECEPTOR

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2015781A4 (en) * 2005-09-12 2009-12-23 Univ Johns Hopkins COMPOSITIONS HAVING ANTIANGIOGENIC ACTIVITY AND USES THEREOF
EP2649095B1 (en) * 2010-12-10 2021-10-06 Aleksander S. Popel Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases
MX2019003895A (es) * 2016-10-04 2019-10-07 Asclepix Therapeutics Inc Compuestos y metodos para activar la señalizacion tie2.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105431162A (zh) * 2013-06-07 2016-03-23 约翰霍普金斯大学 用于治疗血管生成依赖性和淋巴管生成依赖性疾病的生物模拟肽和生物可降解的递送平台
US20160122390A1 (en) * 2013-06-07 2016-05-05 The Johns Hopkins University A biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases
US20180339024A1 (en) * 2015-11-19 2018-11-29 Asclepix Therapeutics, Llc Peptides with anti-angiogenic, anti-lymphangiogenic, and anti-edemic properties and nanoparticle formulations
WO2018208829A1 (en) * 2017-05-08 2018-11-15 Asclepix Therapeutics, Llc Biodegradable microparticles for sustained delivery of anti-angiogenic peptide
WO2019028427A1 (en) * 2017-08-03 2019-02-07 Asclepix Therapeutics, Llc. METHODS OF IDENTIFYING AND PREPARING PHARMACEUTICAL AGENTS TO ACTIVATE TIE2 RECEPTOR

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ADAM C. MIRANDO ET AL.: "A collagen IV–derived peptide disrupts α5β1 integrin and potentiates Ang2/Tie2 signaling", JCI INSIGHT, 21 February 2019 (2019-02-21), pages 1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023222134A1 (zh) * 2022-05-20 2023-11-23 杭州禾泰健宇生物科技有限公司 一种类肽化合物及其应用

Also Published As

Publication number Publication date
KR20210146352A (ko) 2021-12-03
AU2020248438A1 (en) 2021-10-28
ZA202107235B (en) 2023-10-25
WO2020198481A1 (en) 2020-10-01
CA3134816A1 (en) 2020-10-01
EP3946418A4 (en) 2023-02-22
US12540171B2 (en) 2026-02-03
JP7650074B2 (ja) 2025-03-24
EA202192607A1 (ru) 2022-03-03
US20230054032A1 (en) 2023-02-23
IL286625A (en) 2021-12-01
MX2021011727A (es) 2022-01-24
JP2022527276A (ja) 2022-06-01
EP3946418A1 (en) 2022-02-09

Similar Documents

Publication Publication Date Title
US11738064B2 (en) Pharmaceutical composition for preventing and treating eye diseases, containing as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused
CN109715189B (zh) 靶向VE-PTP(HPTP-β)的人源化单克隆抗体
JP2021193115A (ja) 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用
KR20120130752A (ko) 혈관신생-관련된 안질환의 치료를 위한 조성물 및 방법
JP2016522250A (ja) 黄斑浮腫の治療におけるｖｅｇｆアンタゴニストの使用
ES2886542T3 (es) Uso de sirolimus para tratar la degeneración macular asociada con la edad exudativa con edema persistente
JP7650074B2 (ja) 眼疾患を治療するための組成物及び方法
TW201904610A (zh) 用於治療新生血管型青光眼之非抗體vegf拮抗劑
CA3165887A1 (en) Use of fusion protein in treatment of age-related macular degeneration
EP4251204A1 (en) Vegf antagonist for use in methods for treating ocular diseases
JP6944463B2 (ja) 眼疾患の治療のための組成物及び方法
Smith et al. Therapeutic monoclonal antibodies and fragments: Ranibizumab
KR20140130725A (ko) 트롬빈 유래 펩타이드를 포함하는 망막증 또는 녹내장 치료용 조성물
KR20220051791A (ko) Fas 신호전달 억제용 펩타이드를 포함하는 황반변성 예방 또는 치료용 조성물
WO2026036282A1 (en) Multispecific fusion proteins targeting angiogenic factors
EP4429693B1 (en) Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion
WO2025054768A1 (en) Multispecific fusion proteins targeting angiogenic and inflammatory factors
WO2026040746A1 (en) Multispecific fusion proteins targeting angiogenic and inflammatory factors
EP2772498B1 (en) Polypeptides inhibiting neovascularization and uses thereof
HK40115628B (en) Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion
HK40115628A (en) Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion
KR20260019535A (ko) 보체 항체-약물 접합체
CN121194795A (zh) 膜联蛋白a5蛋白质与抗vegf药剂作为组合疗法用于治疗黄斑水肿或视网膜静脉阻塞

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211126

WD01 Invention patent application deemed withdrawn after publication